The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Boehringer Ingelheim’s new oral therapy, BI 1015550, to treat patients with idiopathic pulmonary fibrosis (IPF).
Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.
Merck and Ridgeback Biotherapeutics have initiated a Phase III clinical trial to evaluate investigational oral antiviral therapeutic molnupiravir to prevent Covid-19 infection.
US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.
Preliminary findings from a study funded by the National Institutes of Health (NIH) has found that pregnant women with severe Covid-19 symptoms had a higher risk of complications during and after pregnancy.
Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.
The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.
AstraZeneca announced that it has secured regulatory approval from China’s National Medical Products Administration (NMPA) for Symbicort Turbuhaler, an anti-inflammatory reliever to relieve symptoms of mild asthma.
Humanigen has announced an expansion to the Cooperative Research and Development Agreement (CRADA) with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.